

**FULCRUM PHARMA PLC**

("Fulcrum" or "the Group" or "the Company")

**Board Appointment**

Fulcrum Pharma plc (AIM: FUL), the drug development and strategic outsourcing services company, is pleased to announce that Angus Bell will join the Board of Fulcrum as a Non-Executive Director with effect from 9th March 2006.

Dr. Bell has more than thirty years' experience in the pharmaceutical industry including a number of strategic and management roles at Quintiles and Glaxo. He brings significant experience in the strategic development of new businesses, particularly in the pre-clinical area, and will be a valuable addition to Fulcrum's board as the company moves forward.

Dr. Bell worked at Glaxo where he made significant contributions to the design and development of several marketed medicines (Zantac™, Imigran™, Zofran™ and Serevent™). After the formation of Glaxo Wellcome, Dr. Bell led a programme to re-design the key business processes of R&D including drug candidate selection, clinical development, and new product delivery. At Quintiles Edinburgh facility Dr. Bell was Chief Operating Officer for Pre-clinical Services and General Manager of Early Development and Laboratory Services.

Dr. Bell is also a Non-Executive Director of Pharmaceutical Profiles Ltd, and of Maccine Pty Ltd. Dr Bell holds a first degree in biochemistry from the University of Leeds and a PhD from CNAA (London).

**Jon Court, Chief Executive of Fulcrum Pharma, said:** "I am delighted to welcome Angus to the Board. Angus brings a wealth of experience to Fulcrum particularly in the preclinical arena. Recently Fulcrum announced that it planned to strengthen the Board with additional expertise from the service sector. We feel that Angus' experience, in particular that gained from his various roles at Quintiles, will be instrumental in helping Fulcrum drive the Company's global service model further forward and maximise the exciting opportunities that lie ahead."

**Angus Bell said:** "Fulcrum offers a unique approach to global services around drug development. I am very excited about joining the Board and applying my knowledge and expertise to Fulcrum's business strategy and core operations."

**FOR FURTHER INFORMATION, PLEASE CONTACT:**

**Fulcrum Pharma PLC**

Ashley Nagle, Business Development Director

**Tel: 0870 712 0538**

### **Notes for editors**

#### **About Fulcrum Pharma plc**

Fulcrum Pharma plc is an independent, drug development company that offering global virtual drug development and strategic outsourcing services to the pharmaceutical industry. The Group is expert in the design, execution and delivery of drug development programmes and works with emerging biotech / pharma companies as well larger Pharma companies.

Through Fulcrum Pharma's services to its clients, the Directors believe that there is the capacity to deliver products faster and more efficiently to the global pharmaceutical market. Fulcrum Pharma does this by using its skills in the design of drug programmes that deliver the necessary information for decision-making and product development. In so doing, Fulcrum Pharma works closely with its clients to meet their strategic R&D goals.

Fulcrum Pharma is listed on the Alternative Investment Market of the London Stock Exchange having successfully floated in March 2000.